The goal of this review is to report a balanced perspective of current evidence for efficacy of treatments for coronavirus disease 2019(COVID-19)against the historical safety of these treatments as of May 2021.We pres...The goal of this review is to report a balanced perspective of current evidence for efficacy of treatments for coronavirus disease 2019(COVID-19)against the historical safety of these treatments as of May 2021.We preselected therapies of interest for COVID-19 based on national guidelines and modified over time.We searched PubMed and Medline for these specific COVID-19 treatments and data related to their efficacy.We also searched for prior randomized controlled trials of each therapy to assess adverse effects,and we obtained the Food and Drug Administration Approval label for this information.Several drugs have been approved for the treatment of COVID-19,and many more are under study.This includes dexamethasone,remdesivir,hydroxychloroquine/chloroquine,lopinvir/ritonavir,interferon or interleukin inhibitors,convalescent plasma and several vitamins and minerals.The strongest evidence for benefit is mortality benefit with dexamethasone in patients with COVID-19 and hypoxemia,although there is a signal of harm if this is started too early.There are several other promising therapies,like interleukin inhibitors and ivermectin.Hydroxychloroquine/chloroquine,lopinvir/ritonavir,and convale-scent plasma do not have enough evidence of benefit to outweigh the known risks of these drugs.展开更多
文摘The goal of this review is to report a balanced perspective of current evidence for efficacy of treatments for coronavirus disease 2019(COVID-19)against the historical safety of these treatments as of May 2021.We preselected therapies of interest for COVID-19 based on national guidelines and modified over time.We searched PubMed and Medline for these specific COVID-19 treatments and data related to their efficacy.We also searched for prior randomized controlled trials of each therapy to assess adverse effects,and we obtained the Food and Drug Administration Approval label for this information.Several drugs have been approved for the treatment of COVID-19,and many more are under study.This includes dexamethasone,remdesivir,hydroxychloroquine/chloroquine,lopinvir/ritonavir,interferon or interleukin inhibitors,convalescent plasma and several vitamins and minerals.The strongest evidence for benefit is mortality benefit with dexamethasone in patients with COVID-19 and hypoxemia,although there is a signal of harm if this is started too early.There are several other promising therapies,like interleukin inhibitors and ivermectin.Hydroxychloroquine/chloroquine,lopinvir/ritonavir,and convale-scent plasma do not have enough evidence of benefit to outweigh the known risks of these drugs.
